UCLA research highlights delayed Huntington’s disease diagnosis for Black patients

Pfiz­er said it ex­pects few­er peo­ple will be need­ed to com­plete its Phase III tri­al of Val­ne­va’s Ly­me dis­ease vac­cine can­di­date than orig­i­nal­ly thought. The

Im­pel Phar­ma­ceu­ti­cals is now con­sid­er­ing strate­gic al­ter­na­tives for its fu­ture, in­clud­ing sell­ing the com­pa­ny as a whole or merg­ing with an­oth­er com­pa­ny, months af­ter ad­mit­ting dwin­dling